Mounjaro Risks: What the Clinical Evidence Tells Us

What the SURMOUNT trials found about tolerability

The SURMOUNT-1 trial, whose results were published in the New England Journal of Medicine, followed 2,539 adults over 72 weeks across tirzepatide's full dose range. The picture that emerged was consistent: Mounjaro produced meaningful weight reduction, but the side-effect story was almost entirely gastrointestinal. Nausea, diarrhoea, vomiting, constipation, and indigestion were the events reported most often, and they clustered around the period immediately after each dose step, then tended to settle. Around one in five participants at the highest dose discontinued treatment, with GI intolerance cited most frequently as the reason. That figure is worth holding in mind without alarm: it also means roughly four in five stayed the course at the top dose, and discontinuation rates were lower at earlier dose levels. The slow titration schedule (beginning at 2.5 mg precisely because it allows the body to adjust) is designed specifically to reduce this burden. NICE's appraisal of tirzepatide (TA1026) reviewed the same trial data and endorsed the medicine's overall benefit-risk balance for eligible adults. That endorsement rests on a clinical assessment framework, not on blanket access: your health history, any existing conditions, and current medicines all shape whether those benefits outweigh the risks of tirzepatide for you personally.

Serious risks that warrant prompt medical attention

Rare does not mean ignorable. Several risks associated with Mounjaro require you to seek medical help quickly if they appear. The one that generated a formal UK regulatory communication is acute pancreatitis: in January 2026, the MHRA issued a Drug Safety Update on GLP-1 receptor agonists, including tirzepatide, because pancreatitis, though infrequent, can be serious. The warning symptom is severe stomach pain that does not ease and radiates through to the back, with or without vomiting. That combination needs urgent assessment, not a wait-and-see approach. Gallbladder problems (gallstones and inflammation) are also more common in people losing weight rapidly, and the NHS tirzepatide page lists these among the side effects to watch for. Severe dehydration is another concern: if vomiting or diarrhoea is persistent and you are unable to keep fluids down, kidney function can be affected. Allergic reactions, including swelling of the face, lips or throat, require emergency help. Finally, anyone who notices a change in mood, low mood, or thoughts of self-harm while on treatment should contact their prescriber or GP promptly. None of these are common outcomes in the trial data, but they are the signals that should not be waited out at home. A full account of the risks and side effects of Mounjaro, with plain-language explanation, is available on our tirzepatide risks page.

Risks specific to certain groups: contraception, HRT and surgery

Some of the most practically important Mounjaro risks in the UK apply to specific groups rather than everyone. Women using oral contraceptives need to know that tirzepatide slows gastric emptying enough to potentially reduce absorption of the pill. NHS guidance is clear: add a barrier method such as condoms for the first four weeks of treatment and for four weeks after each dose increase. This is a tirzepatide-specific recommendation; the equivalent evidence for semaglutide is less established. For women using oral HRT, NHS England advises considering a switch to a transdermal form (a patch or gel) while on tirzepatide, for the same absorption reason. It is worth raising this with your doctor before you begin, rather than mid-treatment. If you are having any surgical procedure, tell every member of the clinical team, including the anaesthetist, that you are on tirzepatide; delayed gastric emptying has implications for anaesthesia safety. Our detailed Mounjaro side effects page covers these group-specific considerations at greater length, and our long-term risks page addresses what is known (and what remains under ongoing surveillance) beyond the trial periods. Mounjaro carries a Black Triangle (▼) designation from the MHRA, meaning it is subject to additional monitoring; that is standard for newer medicines and does not signal unusual danger, but it does mean reporting side effects matters. The Yellow Card scheme at yellowcard.mhra.gov.uk accepts reports from patients directly.

How a prescriber weighs these risks before approving treatment

A conversation about Mounjaro risks in the UK is never just a list of possible side effects, it is a personalised calculation. A history of pancreatitis, certain gallbladder conditions, or a family history of medullary thyroid cancer are among the cancer-related factors that shift the risk-benefit balance and may mean tirzepatide is not the right choice. Existing medicines that affect gut motility, blood sugar, or thyroid function also come into the picture. At nume, a GPhC-registered Independent Prescriber reads every consultation personally, your answers are reviewed by a named clinician, not filtered by an automated tool. That review is what makes a same-day clinical assessment meaningful rather than a formality. If you are wondering whether your own health history puts you in a group where the risks outweigh the benefits, that is exactly the question the consultation is designed to answer. Our clinical team and the wider service are described on the about us page. If you have already started treatment elsewhere and have questions about a specific symptom, our prescribers provide priority aftercare seven days a week, get in touch if something feels off. For a broader look at the mounjaro risks UK patients ask about most, our overview page pulls together the full picture. When you are ready to talk through your own suitability, start your free consultation and a prescriber will discuss both the evidence and your individual health profile.